New Alzheimer’s drug shows promise in small trial

Treatment reduced brain plaques, but effects on mental function not clear

brain scans

PLAQUE BUSTER  In a trial of 165 people, brain scans showed reductions in amyloid-beta plaques (red) in people given the antibody aducanumab compared with a placebo. Higher doses caused more amyloid reduction. 

J. Sevigny et al/Nature 2016

This article is only available to Science News subscribers.

Subscribers, enter your e-mail address to access our archives.

Not a subscriber?

Science News is a nonprofit.

Support us by subscribing now.

More Stories from Science News on Neuroscience

From the Nature Index

Paid Content